These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29953581)

  • 1. Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options.
    Ference BA
    Clin Pharmacol Ther; 2019 Mar; 105(3):568-581. PubMed ID: 29953581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
    Khera AV; Rader DJ
    Trends Cardiovasc Med; 2009 Aug; 19(6):195-201. PubMed ID: 20211435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.
    Lanktree MB; Thériault S; Walsh M; Paré G
    Am J Kidney Dis; 2018 Feb; 71(2):166-172. PubMed ID: 28754456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9: Regulation and Target for Drug Development for Dyslipidemia.
    Burke AC; Dron JS; Hegele RA; Huff MW
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():223-244. PubMed ID: 27575716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps.
    Ference BA
    Curr Opin Lipidol; 2015 Dec; 26(6):566-71. PubMed ID: 26780009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mendelian randomization: Its impact on cardiovascular disease.
    Kawashiri MA; Tada H; Nomura A; Yamagishi M
    J Cardiol; 2018 Oct; 72(4):307-313. PubMed ID: 29801689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of Circulating Protein Levels With Lipid Fractions in the General Population.
    Figarska SM; Gustafsson S; Sundström J; Ärnlöv J; Mälarstig A; Elmståhl S; Fall T; Lind L; Ingelsson E
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2505-2518. PubMed ID: 30354202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.
    Williams DM; Bandres-Ciga S; Heilbron K; Hinds D; Noyce AJ; ;
    Ann Neurol; 2020 Nov; 88(5):1043-1047. PubMed ID: 32841444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.
    Farnier M
    Curr Cardiol Rep; 2016 Jul; 18(7):65. PubMed ID: 27216845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.
    Athyros VG; Mikhailidis DP; Kakafika AI; Karagiannis A; Hatzitolios A; Tziomalos K; Ganotakis ES; Liberopoulos EN; Elisaf M
    Curr Drug Targets; 2007 Mar; 8(3):483-8. PubMed ID: 17348840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.
    Musunuru K; Kathiresan S
    Circ Res; 2016 Feb; 118(4):579-85. PubMed ID: 26892959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRAC channels as targets for drug discovery and development.
    Stauderman KA
    Cell Calcium; 2018 Sep; 74():147-159. PubMed ID: 30075400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.